Rockwell Medical (NASDAQ: RMTI) Initiated at Outperform, $12 Target Print E-mail
Tuesday, 13 October 2009 12:35

On 10/12/09, Wedbush Morgan initiated coverage of Rockwell Medical (NASDAQ: RMTI) with an outperform rating and $12 per share fair value price target with a summary of the major points included below.

 

 

Rockwell Medical (NASDAQ: RMTI): Wedbush Morgan 10/12/09 (follow preceding link to view or download the PDF report)

 

Click here to visit the ProActive News Room page for RMTI.

 

1.) We believe that Rockwell is poised to capitalize on a potentially high-revenue and best-in-class treatment for anemia among its existing dialysate customers.

 

2.) We believe that SFP is poised to benefit from anticipated changes to government funding of dialysis clinics.

 

3.) We predict that Rockwell has cash runway into late 2011.

 

4.) Our fair value of $12 per share suggests that Rockwell holds the potential to increase 52% in the near-term.

 

Disclosure: Long RMTI

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter